Clinical trials in cancer and autoimmune diseases: Immutep’s CEO Marc Voigt provides an update
30 Jul 2024 - Immutep Limited (ASX:IMM) CEO and Executive Director Marc Voigt discusses Phase III design for a trial in non-small cell lung cancer, positive results in head and neck cancer, and clearance for a Phase I study in autoimmune diseases.